Tejara Capital Ltd Has $1.43 Million Position in OPKO Health, Inc. $OPK

Key Points

• Tejara Capital Ltd reduced its stake in OPKO Health by 29.8%, selling 365,306 shares, and now holds 860,344 shares valued at approximately $1.4 million.
• OPKO Health reported a quarterly EPS of (0.19), missing estimates, with revenue of $156.8 million, down 13.9% year-over-year.
• Recent analyst activity includes Wall Street Zen's downgrade of OPKO from "hold" to "sell" while LADENBURG THALM/SH SH upgraded it to "strong-buy."

Tejara Capital Ltd trimmed its position in shares of OPKO Health, Inc. (NASDAQ:OPK - Free Report) by 29.8% during the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 860,344 shares of the biotechnology company's stock after selling 365,306 shares during the quarter. Tejara Capital Ltd owned 0.11% of OPKO Health worth $1,428,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Oak Thistle LLC acquired a new position in OPKO Health during the first quarter worth about $26,000. Cerity Partners LLC purchased a new position in shares of OPKO Health during the first quarter valued at approximately $36,000. Wealth Enhancement Advisory Services LLC lifted its stake in shares of OPKO Health by 75.3% during the fourth quarter. Wealth Enhancement Advisory Services LLC now owns 28,908 shares of the biotechnology company's stock valued at $42,000 after buying an additional 12,417 shares during the period. Pallas Capital Advisors LLC purchased a new position in OPKO Health during the first quarter worth approximately $43,000. Finally, Zacks Investment Management purchased a new position in OPKO Health during the fourth quarter worth approximately $49,000. 64.63% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity

In other OPKO Health news, CEO Phillip Md Et Al Frost acquired 675,000 shares of the stock in a transaction dated Friday, August 8th. The shares were bought at an average price of $1.32 per share, with a total value of $891,000.00. Following the purchase, the chief executive officer directly owned 214,676,448 shares of the company's stock, valued at approximately $283,372,911.36. This trade represents a 0.32% increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 49.69% of the stock is owned by corporate insiders.

Analyst Ratings Changes

Several equities research analysts have recently issued reports on OPK shares. Barrington Research reissued an "outperform" rating and issued a $2.25 price objective on shares of OPKO Health in a research report on Thursday, May 1st. LADENBURG THALM/SH SH upgraded shares of OPKO Health to a "strong-buy" rating in a research note on Tuesday, July 8th. Zacks Research upgraded shares of OPKO Health from a "strong sell" rating to a "hold" rating in a research note on Thursday, August 14th. Wall Street Zen downgraded shares of OPKO Health from a "hold" rating to a "sell" rating in a research note on Monday, May 5th. Finally, JPMorgan Chase & Co. started coverage on shares of OPKO Health in a research note on Friday, April 25th. They set a "neutral" rating on the stock. One research analyst has rated the stock with a Strong Buy rating, three have given a Buy rating and two have issued a Hold rating to the company. Based on data from MarketBeat, the stock has an average rating of "Moderate Buy" and an average price target of $2.75.

OPKO Health Price Performance

OPKO Health stock traded down $0.04 during trading hours on Tuesday, hitting $1.36. 1,239,685 shares of the company traded hands, compared to its average volume of 3,826,976. The firm has a market cap of $1.08 billion, a P/E ratio of -5.44 and a beta of 1.19. The company has a quick ratio of 3.02, a current ratio of 3.41 and a debt-to-equity ratio of 0.25. The firm's 50-day simple moving average is $1.33 and its two-hundred day simple moving average is $1.46. OPKO Health, Inc. has a 1-year low of $1.11 and a 1-year high of $2.0350.

OPKO Health (NASDAQ:OPK - Get Free Report) last announced its quarterly earnings data on Thursday, July 31st. The biotechnology company reported ($0.19) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.12) by ($0.07). The business had revenue of $156.80 million during the quarter, compared to analyst estimates of $165.74 million. OPKO Health had a negative return on equity of 13.17% and a negative net margin of 26.68%.The business's revenue for the quarter was down 13.9% on a year-over-year basis. During the same period in the prior year, the firm earned ($0.01) EPS. As a group, analysts forecast that OPKO Health, Inc. will post -0.25 earnings per share for the current fiscal year.

About OPKO Health

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test.